Grace Therapeutics, Inc.

NasdaqCM:GRCE Stock Report

Market Cap: US$36.2m

Grace Therapeutics Future Growth

Future criteria checks 3/6

Grace Therapeutics is forecast to grow earnings and revenue by 53.5% and 58.7% per annum respectively while EPS is expected to grow by 51.7% per annum.

Key information

53.5%

Earnings growth rate

51.69%

EPS growth rate

Pharmaceuticals earnings growth14.4%
Revenue growth rate58.7%
Future return on equityn/a
Analyst coverage

Low

Last updated24 Apr 2026

Recent future growth updates

Recent updates

Analysis Article • Feb 19

Companies Like Grace Therapeutics (NASDAQ:GRCE) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Sep 02

Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Apr 20

We're Keeping An Eye On Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Nov 14

Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • May 10

We're Not Very Worried About Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 11

Acasti Pharma GAAP EPS of -$0.10

Acasti Pharma press release (NASDAQ:ACST): Q1 GAAP EPS of -$0.10. Cash, cash equivalents and short-term investments of $38.4M. Given certain cost savings and overall efficiencies implemented across the organization, management believes that it now has sufficient capital to fund operations through at least March 2024, allowing for the advancement of GTX-104 through Phase 3 and advancing GTX-102 and GTX-101 to key value inflection points. The company remains on track to initiate the PK bridging study of GTX-102 in the third calendar quarter of 2022 and is expected to report out topline results on schedule before the end of calendar 2022. Assuming the PK bridging study meets its primary endpoint, and based on the FDA’s subsequent guidance, the Company plans to conduct a Phase 3 safety and efficacy trial in Ataxia Telangiectasia (A-T) patients. The Phase 3 study is expected to be initiated in the second half of calendar 2023.

Earnings and Revenue Growth Forecasts

NasdaqCM:GRCE - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/20294514-10N/A1
3/31/20286-16-68-152
3/31/2027N/A-15-67-92
3/31/2026N/A-14-27-102
12/31/2025N/A-6-10-10N/A
9/30/2025N/A-8-12-12N/A
6/30/2025N/A-10-13-13N/A
3/31/2025N/A-10-15-15N/A
12/31/2024N/A-13-14-14N/A
9/30/2024N/A-12-12-12N/A
6/30/2024N/A-11-10-10N/A
3/31/2024N/A-13-12-12N/A
12/31/2023N/A-39-14-14N/A
9/30/2023N/A-40-15-15N/A
6/30/2023N/A-42-17-17N/A
3/31/2023N/A-42-16-16N/A
12/31/2022N/A-17-16-16N/A
9/30/2022N/A-17-17-17N/A
6/30/2022N/A-11-19-19N/A
3/31/2022N/A-10-17-17N/A
12/31/20210-12-16-16N/A
9/30/20210-11-15-15N/A
6/30/20210-18-14-14N/A
3/31/20210-20-14-14N/A
12/31/202003-16-15N/A
9/30/2020N/A-6-19-18N/A
6/30/2020N/A-21-21-20N/A
3/31/2020N/A-26-23-23N/A
12/31/2019N/A-56-29-29N/A
9/30/2019N/A-46N/A-29N/A
6/30/2019N/A-42N/A-27N/A
3/31/2019N/A-39N/A-25N/A
12/31/2018N/A-31N/A-19N/A
9/30/2018N/A-34N/A-16N/A
6/30/2018N/A-20N/A-13N/A
3/31/2018N/A-17N/A-10N/A
3/31/2017N/A-8N/A-5N/A
11/30/20160-7N/A-5N/A
8/31/20160-7N/A-5N/A
5/31/20160-6N/A-6N/A
2/29/2016N/A-5N/A-5N/A
11/30/20150-5N/A-6N/A
8/31/20150-1N/A-6N/A
5/31/20150-3N/A-6N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GRCE is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.5%).

Earnings vs Market: GRCE is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: GRCE is expected to become profitable in the next 3 years.

Revenue vs Market: GRCE is forecast to have no revenue next year.

High Growth Revenue: GRCE is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if GRCE's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/11 05:05
End of Day Share Price 2026/05/11 00:00
Earnings2025/12/31
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Grace Therapeutics, Inc. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raymond MyersBenchmark Company
Mayank MamtaniB. Riley Securities, Inc.
Douglas LoeCantor Fitzgerald Canada Corporation